Considering the unsatisfactory response rate of anti-PD-1/PD-L1, our previous work found that the PGRN promoted the dysfunction of CD8 + T cells through the interaction of PD-L1 on TAMs with PD-1 on CD8+T cells [53], these work give us a reasonable idea: Whether the combination of ablation of PGRN and anti-PD-1 therapy showed better antitumor effects in breast cancer? The gene discussed is CD8A; the disease is breast carcinoma.